Printer Friendly

SYNTEX-SYNERGEN JOINT VENTURE BEGINS ALS PHASE I STUDY

 SYNTEX-SYNERGEN JOINT VENTURE BEGINS ALS PHASE I STUDY
 BOULDER, Colo., May 13 /PRNewswire/ -- The Syntex-Synergen Neuroscience Joint Venture announced today the initiation of a Phase I clinical trial of ciliary neurotrophic factor (CNTF) for the potential treatment of amyotrophic lateral sclerosis (ALS). The first study is being conducted at Tufts University Medical Center under the direction of Theodore Munsat, M.D., professor of neurology and pharmacology.
 CNTF is a nerve repair factor normally produced by the body in response to damage to peripheral nerves. A lethal disease with no known treatment, ALS, commonly called Lou Gehrig's disease, causes progressive degeneration of the motor nerves. Preclinical studies have demonstrated that CNTF may be useful in preventing or slowing degeneration of the primary motor neurons that ultimately leads to death for people with ALS.
 The initial clinical trial will focus on CNTF's safety and pharmacokinetics of several single doses in a small number of patients.
 The Syntex-Synergen Neuroscience Joint Venture was formed by the two companies in 1990 to develop new protein-based therapeutics for the treatment of neurological diseases. CNTF is the first factor from the joint venture to reach human clinical trials. Other proteins in development are nerve growth factor, basic fibroblast growth factor and Parkinson's Factor.
 Synergen Inc. (NASDAQ: SYGN) is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted towards products to treat inflammatory diseases, chronic ulcers and neurological diseases.
 Syntex Corp. (NYSE: SYN) is an international health care company which discovers, develops, manufactures and markets human and animal pharmaceutical products and medical diagnostic systems.
 -0- 5/13/92
 /CONTACT: Linda Thomas of Syntex, 415-852-1321; or Debra Bannister of Synergen, 303-938-6242/
 (SYGN SYN) CO: Synergen Inc.; Syntex Corp. ST: Colorado IN: MTC SU: JVN


MC -- DV012 -- 9868 05/13/92 16:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:303
Previous Article:EXCALIBUR TECHNOLOGIES FILES A REGISTRATION STATEMENT FOR PROPOSED OFFERING
Next Article:LUKENS RENAMES WASHINGTON STEEL COMPANIES AFTER ACQUISITION
Topics:


Related Articles
SYNERGEN EXPANDS INTO EUROPE
SYNERGEN AND INSITE VISION ANNOUNCE COOPERATIVE AGREEMENT TO EVALUATE ANTRIL FOR OPHTHALMIC APPLICATIONS
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
SYNERGEN DEDICATES NEW COMMERCIAL-SCALE MANUFACTURING PLANT
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
SYNERGEN BEGINS OPERATIONS IN JAPAN
SYNERGEN REPORTS 1992 FINANCIAL RESULTS
SYNTEX-SYNERGEN JOINT VENTURE ALS STUDY UNDERWAY
SYNERGEN'S ANTRIL SHOWS PROMISE IN RHEUMATOID ARTHRITIS; A SECOND PHASE II TRIAL TO START IN EUROPE IN EARLY 1994
SYNERGEN REPORTS 1993 FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters